Securities code: 603567 securities abbreviation: Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) Announcement No.: pro 2022-005 Heilongjiang Zbd Pharmaceutical Co.Ltd(603567)
Announcement on the approval of Xiaoer re Suqing syrup as a second grade protected variety of national traditional Chinese Medicine
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Recently, the website of the State Drug Administration (hereinafter referred to as the “State Drug Administration”) released the announcement on the protected varieties of traditional Chinese medicine (No. 7) (No. 7 in 2022), which shows that the Xiaoer re Suqing syrup produced by Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) (hereinafter referred to as the “company” or ” Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) “) approved by the State Drug Administration is the first class II protected variety of traditional Chinese medicine, and the protected variety number is zyb2072022001, The term of protection is seven years from the date of announcement. The relevant information of Xiaoer re Suqing syrup is described as follows:
1、 Basic information of drugs
Xiaoer re Suqing syrup is a commonly used Chinese patent medicine for upper respiratory tract infection in pediatrics. The formula includes honeysuckle, Forsythia suspensa, Scutellaria baicalensis, Radix Isatidis, radix puerariae, bupleurum, rhubarb and buffalo horn. It has the effects of clearing heat and detoxification, purging fire and swallowing. It is clinically used for the treatment of children’s cold caused by exogenous wind heat, such as high fever, headache, sore throat, nasal congestion, runny nose, cough and dry stool. It has remarkable curative effect on a series of symptoms caused by children’s upper respiratory tract infection. The cumulative R & D investment of the traditional Chinese medicine protection project of Xiaoer re Suqing syrup is about 6.75 million yuan.
According to the data of Intranet, in 2020, the terminal market scale of children’s hot quick clear syrup hospital was 3.55 million yuan, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) accounting for 96.62%; The scale of retail terminal market is 1.28 million yuan, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) accounting for 19.35%. It belongs to pediatric cold medicine and Chinese patent medicine together with Xiaoer resuqing syrup. The competitive varieties include douqiao Qingre Granule, Xiaoer chaigui antipyretic granule, etc.
2、 Impact on the company
This time, Xiaoer re Suqing syrup was approved as the first grade II protected variety of traditional Chinese medicine, which protected the construction of the company’s innovation ability, helped the company give full play to the intellectual property advantages of leading products and further improved the market share.
It is hereby announced.
Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) board of directors January 24, 2022
